BINV: BI-1808 moves toward randomized ovarian cancer trial amid conditional capital raise
BINV shares early ovarian cancer data for BI-1808 with pembrolizumab and proposes a SEK 430m rights issue, per TradingView summary of the filing.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
BINV reported that BI-1808 combined with pembrolizumab produced a 24% objective response rate and a 53% disease control rate in heavily pretreated ovarian cancer patients, according to TradingView. The results support plans for a randomized triplet study in 2027.
The company has also proposed a rights issue of SEK 430 million to fund priority programs. Its cash runway is expected to last through the end of 2027, but only if the proceeds from the offering are fully covered.
why it matters
For investors, the key question is whether the company can fund development without heavy dilution. Because the cash runway depends on the rights issue being covered, the outcome of the raise matters more for near-term assessment than the trial data alone. The story concerns a single small company rather than the broader market.
tags
instruments
sources
- BINV: BI-1808 advances toward randomized ovarian-cancer testing amid a conditional SEK 430m raise — TradingView, 29 October 2026 at 16:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗